Richard Wood led Eli Lilly and Co. through prosperous times, thanks to products like Prozac. Colleagues say his foresight paid off.

As we begin to reopen, we owe it to those we've lost to proceed gradually, making decisions based on what data shows about the virus' spread.

The U.S. Food and Drug Administration on Friday approved a drug to treat lung and thyroid cancers driven by a specific genetic mutation that Eli Lilly and Co acquired with its 2019 purchase of Loxo Oncology.

* LILLY RECEIVES U.S. FDA APPROVAL FOR RETEVMO™ (SELPERCATINIB), THE FIRST THERAPY SPECIFICALLY FOR PATIENTS WITH ADVANCED RET-DRIVEN LUNG AND THYROID CANCERS

Eil Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces a protein involved in cell signaling. […]

Junshi Biosciences, a China-based biopharmaceutical company, and Eli Lilly and Company (LLY) have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19. Junshi SARS-CoV-2 Antibodies, or JS016, is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface spike protein receptor binding domain. It is jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science.